Key result
Valve-in-valve TAVR was associated with lower odds of 30-day mortality compared to reoperative surgical aortic valve replacement in matched patients.
Why the study?
Contemporary head-to-head comparisons of 30-day outcomes and readmissions between VIV-TAVR and high-risk re-SAVR using large, multicentre national data were needed.
Does valve-in-valve transcatheter aortic valve replacement reduce 30-day mortality and morbidity compared to reoperative surgical aortic valve replacement in high-risk adult patients with degenerated bioprosthetic aortic valves?
Cohort (n=6,815)
Yes
Does valve-in-valve transcatheter aortic valve replacement reduce 30-day mortality and morbidity compared to reoperative surgical aortic valve replacement in high-risk adult patients with degenerated bioprosthetic aortic valves?
In high-risk patients with degenerated bioprosthetic aortic valves, VIV-TAVR is associated with significantly lower 30-day mortality, morbidity, and major bleeding compared to re-SAVR.
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“The problem with using these administrative databases are that they do lack granular data, so they don't have any CT or echo information for example. This does provide some longitudinal follow-up, but it doesn't really give you the best sense of what things will look like long-term.”
“Not much data are available comparing the outcomes of valve-in-valve TAVR with reoperative SAVR. Though the short-term outcomes of the two procedures appear similar in limited data that is available, the long-term durability of valve-in-valve TAVR still needs to be evaluated.”
“SAVR and valve-in-valve TAVR should not be seen as competitive procedures -- they should instead be seen as complementary. Depending on patient comorbidities, some patients may have better outcomes after SAVR, while other patients may fare better outcomes with valve-in-valve TAVR.”
May support preferring valve-in-valve TAVR in high-risk patients; leaves open need for randomized confirmation of mortality benefit.
AIMS: We sought to perform a head-to-head comparison of contemporary 30-day outcomes and readmissions between valve-in-valve transcatheter aortic valve replacement (VIV-TAVR) patients and a matched cohort of high-risk reoperative surgical aortic valve replacement (re-SAVR) patients using a large, multicentre, national database. METHODS AND RESULTS: We utilized the nationally weighted 2012-16 National Readmission Database claims to identify all US adult patients with degenerated bioprosthetic aortic valves who underwent either VIV-TAVR (n = 3443) or isolated re-SAVR (n = 3372). Thirty-day outcomes were compared using multivariate analysis and propensity score matching (1:1). Unadjusted, VIV-TAVR patients had significantly lower 30-day mortality (2.7% vs. 5.0%), 30-day morbidity (66.4% vs. 79%), and rates of major bleeding (35.8% vs. 50%). On multivariable analysis, re-SAVR was a significant risk factor for both 30-day mortality [adjusted odds ratio (aOR) of VIV-SAVR (vs. re-SAVR) 0.48, 95% confidence interval (CI) 0.28-0.81] and 30-day morbidity [aOR for VIV-TAVR (vs. re-SAVR) 0.54, 95% CI 0.43-0.68]. After matching (n = 2181 matched pairs), VIV-TAVR was associated with lower odds of 30-day mortality (OR 0.41, 95% CI 0.23-0.74), 30-day morbidity (OR 0.53, 95% CI 0.43-0.72), and major bleeding (OR 0.66, 95% CI 0.51-0.85). Valve-in-valve TAVR was also associated with shorter length of stay (median savings of 2 days, 95% CI 1.3-2.7) and higher odds of routine home discharges (OR 2.11, 95% CI 1.61-2.78) compared to re-SAVR. CONCLUSION: In this large, nationwide study of matched high-risk patients with degenerated bioprosthetic aortic valves, VIV-TAVR appears to confer an advantage over re-SAVR in terms of 30-day mortality, morbidity, and bleeding complications. Further studies are warranted to benchmark in low- and intermediate-risk patients and to adequately assess longer-term efficacy.
No takes yet. Share an insight, caveat, or question.
Hirji et al. (2020) conducted a cohort in Degenerated bioprosthetic aortic valves (n=6,815). Valve-in-valve transcatheter aortic valve replacement (VIV-TAVR) vs. Reoperative surgical aortic valve replacement (re-SAVR) was evaluated on 30-day mortality (OR 0.41, 95% CI 0.23-0.74). Valve-in-valve TAVR was associated with lower odds of 30-day mortality compared to reoperative surgical aortic valve replacement in matched patients.
Synapse has enriched 10 related papers. Consider them for comparative context: